Intercept Pharmaceuticals (ICPT) Scheduled to Post Quarterly Earnings on Wednesday

Intercept Pharmaceuticals (NASDAQ:ICPT) will announce its Q4 2017 earnings results before the market opens on Wednesday, February 21st. Analysts expect the company to announce earnings of ($3.39) per share for the quarter.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) opened at $53.41 on Wednesday. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $135.59. The company has a market capitalization of $1,340.00, a P/E ratio of -3.61 and a beta of -2.13. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15.

Several analysts recently commented on ICPT shares. Wedbush reiterated a “buy” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 target price on the stock. Goldman Sachs Group cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Wednesday, November 1st. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $132.90.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals (ICPT) Scheduled to Post Quarterly Earnings on Wednesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/intercept-pharmaceuticals-icpt-scheduled-to-post-quarterly-earnings-on-wednesday.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply